Oct 12 (Reuters) - Natera Inc NTRA.O:
NATERA INC: NATERA TO PRESENT 14 STUDIES AT ESMO, INCLUDING IMVIGOR011 ORAL PRESENTATION
NATERA INC - SIX ORAL PRESENTATIONS HIGHLIGHT SIGNATERA'S ROLE IN SOLID TUMORS
NATERA: ADDITIONAL ORAL PRESENTATIONS INCLUDE RESULTS FROM SUNRISE-4 TRIAL , INTERCEPT TRIAL IN COLORECTAL CANCER, & NATERA'S EARLY CANCER DETECTION PROGRAM